Fsole

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3952212/publications.pdf

Version: 2024-02-01

223 papers	9,336 citations	81900 39 h-index	46799 89 g-index
227 all docs	227 docs citations	227 times ranked	9537 citing authors

#	Article	IF	Citations
1	CD34+CD19â^'CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	1.4	20
2	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	1.4	29
3	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
4	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leukemia and Lymphoma, 2021, 62, 735-738.	1.3	5
5	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Leukemia Research, 2021, 101, 106492.	0.8	0
6	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	3.7	5
7	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	3.7	5
8	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	1.6	127
9	Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms. Cancers, 2021, 13, 2120.	3.7	10
10	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	1.4	37
11	Adverse prognostic impact of complex karyotype (â‰¥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.8	11
12	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	2.5	25
13	Rare germline variant contributions to myeloid malignancy susceptibility. Leukemia, 2020, 34, 1675-1678.	7.2	8
14	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
15	Cytogenetics in the genomic era. Best Practice and Research in Clinical Haematology, 2020, 33, 101196.	1.7	5
16	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.	2.5	4
17	SF3B1: the lord of the rings in MDS. Blood, 2020, 136, 149-151.	1.4	3
18	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood, 2020, 136, 1851-1862.	1.4	112

#	ARTICLE	IF	CITATIONS
19	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	7.2	14
20	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. Blood, 2020, 136, 30-31.	1.4	0
21	Diagnostic and prognostic contribution of targeted NGS in patients with tripleâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E264-E267.	4.1	17
22	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	2.8	6
23	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes and Cancer, 2019, 58, 689-697.	2.8	8
24	The poor prognosis of low hypodiploidy in adults with Bâ€cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	2.5	6
25	Non-del(5q) myelodysplastic syndromesâ€“associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances, 2019, 3, 3579-3589.	5.2	7
26	MPO as a Novel Susceptibility Gene in Myeloid Malignancies. Blood, 2019, 134, 5402-5402.	1.4	1
27	Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2991-2991.	1.4	0
28	Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E152-E154.	4.1	11
29	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics, 2018, 13, 8-18.	2.7	14
30	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Scientific Reports, 2018, 8, 13883.	3.3	11
31	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	2.8	3
32	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood, 2018, 132, 2309-2313.	1.4	38
33	Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 3249.	4.1	7
34	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
35	Transcriptomic rationale for synthetic lethalityâ€targeting <scp>ERCC</scp>1 and <scp>CDKN</scp>1A in chronic myelomonocytic leukaemia. British Journal of Haematology, 2018, 182, 373-383.	2.5	5
36	Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 4351-4351.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	1.4	0
38	Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction. Blood, 2018, 132, 4339-4339.	1.4	0
39	Feasibility of the AML profiler (Skylineâ„¢ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach. Hematological Oncology, 2017, 35, 778-788.	1.7	3
40	Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients. Biopreservation and Biobanking, 2017, 15, 360-365.	1.0	0
41	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. American Journal of Hematology, 2017, 92, E132-E135.	4.1	1
42	Copy number profiling of adult relapsed Bâ€cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. Genes Chromosomes and Cancer, 2017, 56, 810-820.	2.8	21
43	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.8	9
44	Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes and Cancer, 2017, 56, 243-252.	2.8	10
45	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia Research, 2017, 52, 1-7.	0.8	14
46	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget, 2016, 7, 57021-57035.	1.8	26
47	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	4.1	18
48	Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes. Acta Haematologica, 2016, 135, 94-100.	1.4	2
49	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	1.4	140
50	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood, 2016, 128, 2096-2097.	1.4	46
51	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	2.8	7
52	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	1.4	2
53	Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study. , 2016, , .		0
54	Application of Trusight Myeloid Panel on Whole Genome Amplified DNA in Myelodysplastic Syndrome Patients. Blood, 2016, 128, 5519-5519.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	1.4	0
56	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5281-5281.	1.4	0
57	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. Blood, 2016, 128, 957-957.	1.4	0
58	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	3.5	20
59	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a <scp>G</scp>erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	2.8	8
60	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <scp>B</scp> acute lymphoblastic leukemia enrolled in <scp>PETHEMA</scp> protocols. Cancer, 2015, 121, 3809-3817.	4.1	43
61	Correlation of myelodysplastic syndromes with i(17)(q10) and <scp>TP</scp>53 and <scp>SETBP</scp>1 mutations. British Journal of Haematology, 2015, 171, 137-141.	2.5	11
62	Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. Hematology, 2015, 20, 435-441.	1.5	13
63	Fluorescencein situhybridization ofTP53for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3183-3188.	1.3	2
64	Fluorescencein situhybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2015, 56, 242-243.	1.3	1
65	Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S174.	0.4	0
66	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	1.4	1
67	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoS ONE, 2015, 10, e0129375.	2.5	19
68	TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget, 2015, 6, 34437-34445.	1.8	14
69	Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation. Blood, 2015, 126, 1648-1648.	1.4	0
70	Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features. Blood, 2015, 126, 2883-2883.	1.4	0
71	Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome. Blood, 2015, 126, 96-96.	1.4	0
72	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. Clinical Cancer Research, 2014, 20, 1007-1019.	7.0	44

#	ARTICLE	IF	CITATIONS
73	Paraffin Treasures: Do They Last Forever?. Biopreservation and Biobanking, 2014, 12, 281-283.	1.0	11
74	Guidance for laboratories performing molecular pathology for cancer patients. Journal of Clinical Pathology, 2014, 67, 923-931.	2.0	169
75	Translocation t(2;7)(p11.2;q21.2): a rare genetic aberration associated with B-cell lymphoproliferative disorders of marginal-zone origin. Cancer Genetics, 2014, 207, 281-283.	0.4	5
76	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. Cancer Cell, 2014, 26, 509-520.	16.8	158
77	TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. Journal of the American Academy of Dermatology, 2014, 71, 839-841.	1.2	35
78	TERT and AURKA Gene Copy Number Gains Enhance the Detection of Acral Lentiginous Melanomas by Fluorescence in Situ Hybridization. Journal of Molecular Diagnostics, 2014, 16, 198-206.	2.8	28
79	Errors in the interpretation of copy number variations due to the use of public databases as a reference. Cancer Genetics, 2014, 207, 164-167.	0.4	5
80	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	1.4	0
81	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	1.4	0
82	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. Blood, 2014, 124, 3798-3798.	1.4	0
83	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.8	11
84	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763.	2.8	15
85	5qâ^' syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide. Leukemia Research, 2013, 37, 1248-1250.	0.8	8
86	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â^'7/7qâ^' detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.8	16
87	CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. International Journal of Cancer, 2013, 133, 2398-2407.	5.1	92
88	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	2.5	73
89	Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome. Journal of Clinical Oncology, 2013, 31, 916-922.	1.6	65
90	Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescencein situhybridization techniques?. Leukemia and Lymphoma, 2013, 54, 986-995.	1.3	18

#	ARTICLE	IF	CITATIONS
91	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	2.8	44
92	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. British Journal of Haematology, 2013, 163, 47-54.	2.5	13
93	Identification of Temporal and Region-Specific Myocardial Gene Expression Patterns in Response to Infarction in Swine. PLoS ONE, 2013, 8, e54785.	2.5	32
94	Time Changes In Predictive Power Of MDS Prognostic Scores â€“ Effects On Revised Scores Such As The IPSS-R, Impact Of Age. Blood, 2013, 122, 1544-1544.	1.4	2
95	Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis. Blood, 2013, 122, 1542-1542.	1.4	0
96	Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group. Blood, 2013, 122, 2556-2556.	1.4	0
97	Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. Blood, 2013, 122, 1551-1551.	1.4	0
98	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	2.5	25
99	Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Research, 2012, 14, R71.	5.0	82
100	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	1.6	584
101	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	1.4	2,458
102	Are ER+PR+ and ER+PRâ˜' breast tumors genetically different? A CGH array study. Cancer Genetics, 2012, 205, 138-146.	0.4	11
103	Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993â€“2007. Leukemia Research, 2012, 36, 1262-1266.	0.8	9
104	ALK status in a primary lung tumour and metachronous metastases. Histopathology, 2012, 60, 843-845.	2.9	3
105	Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leukemia Research, 2012, 36, 264-270.	0.8	19
106	Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?. Leukemia Research, 2012, 36, 832-840.	0.8	21
107	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer, 2012, 118, 127-133.	4.1	43
108	Study of Regulatory T-Cells in Patients with Gastric Malt Lymphoma: Influence on Treatment Response and Outcome. PLoS ONE, 2012, 7, e51681.	2.5	35

#	ARTICLE	IF	CITATIONS
109	Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.. Blood, 2012, 120, 2823-2823.	1.4	0
110	Feasibility of the AMLprofilerâ„¢ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach. Blood, 2012, 120, 4813-4813.	1.4	0
111	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing.. Blood, 2012, 120, 2698-2698.	1.4	0
112	Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD). Blood, 2012, 120, 3803-3803.	1.4	3
113	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	3.5	226
114	Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. Cancer Genetics, 2011, 204, 405-409.	0.4	9
115	Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression?. Blood Cells, Molecules, and Diseases, 2011, 47, 259-261.	1.4	5
116	Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Human Pathology, 2011, 42, 176-184.	2.0	43
117	Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphomas Show a Heterogeneous Genomic Profile: An Oligonucleotide ArrayCGH Approach. Journal of Investigative Dermatology, 2011, 131, 269-271.	0.7	14
118	Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array. Leukemia Research, 2011, 35, e161-e163.	0.8	2
119	Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptaseâ€polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes and Cancer, 2011, 50, 510-517.	2.8	69
120	Cryptic IGH/BCL2 rearrangements with variant FISH patterns in follicular lymphoma. Leukemia Research, 2011, 35, 256-259.	0.8	11
121	Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma. Leukemia Research, 2011, 35, e23-e24.	0.8	5
122	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836.	0.8	11
123	Increased MLL gene rearrangements in amniocytes from fetuses of mothers who smoke. Leukemia Research, 2011, 35, 1066-1069.	0.8	5
124	Prognostic Impact of Monosomal Karyotype in Patients with Myelodysplastic Syndrome and Abnormal Karyotype. A Report From the Spanish Group of MDS (GESMD). Blood, 2011, 118, 1724-1724.	1.4	2
125	CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. Histology and Histopathology, 2011, 26, 71-7.	0.7	16
126	FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. Histology and Histopathology, 2011, 26, 213-21.	0.7	16

#	ARTICLE	IF	CITATIONS
127	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	1.4	174
128	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451.	2.8	68
129	CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour. Genes Chromosomes and Cancer, 2010, 49, 1054-1061.	2.8	10
130	Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. Leukemia Research, 2010, 34, 1242-1245.	0.8	23
131	Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Experimental Dermatology, 2010, 19, 151-153.	2.9	77
132	Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2010, 130, 1126-1135.	0.7	71
133	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 2010, 95, 1798-1800.	3.5	9
134	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.9	429
135	Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance. Blood, 2010, 116, 4022-4022.	1.4	0
136	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.9	78
137	Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping. Cancer Genetics and Cytogenetics, 2009, 191, 97-101.	1.0	7
138	3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Human Pathology, 2009, 40, 1474-1478.	2.0	29
139	FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Research, 2009, 11, 402.	5.0	22
140	FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach. Histology and Histopathology, 2009, 24, 1399-404.	0.7	2
141	Analysis of gene status in cervical dysplastic lesions and squamous cell carcinoma using tissue microarrays. Histology and Histopathology, 2009, 24, 821-9.	0.7	5
142	Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2). Pediatric Blood and Cancer, 2008, 50, 651-654.	1.5	0
143	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes and Cancer, 2008, 47, 1086-1097.	2.8	28
144	FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. Leukemia Research, 2008, 32, 737-742.	0.8	37

#	ARTICLE	IF	CITATIONS
145	New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). Leukemia Research, 2008, 32, 727-736.	0.8	20
146	Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2008, 185, 32-36.	1.0	11
147	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
148	Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?. Tumor Biology, 2007, 28, 221-228.	1.8	15
149	Small supernumerary marker chromosome causing partial trisomy 6p in a child with craniosynostosis. American Journal of Medical Genetics, Part A, 2007, 143A, 1108-1113.	1.2	15
150	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research, 2007, 31, 1315-1317.	0.8	2
151	Gain of multiple copies of the CBFB gene: a new genetic aberration in a case of granulocytic sarcoma. Cancer Genetics and Cytogenetics, 2007, 179, 62-65.	1.0	6
152	Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma. Human Pathology, 2006, 37, 867-873.	2.0	36
153	Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study. American Journal of Surgical Pathology, 2006, 30, 1274-1280.	3.7	121
154	Study of chromosomal abnormalities in 11 cases of cervical dysplasia using comparative genomic hybridization on cotton-lint cervical samples. Cancer Genetics and Cytogenetics, 2006, 164, 61-65.	1.0	2
155	The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genetics and Cytogenetics, 2006, 165, 151-156.	1.0	42
156	Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia. Cancer Genetics and Cytogenetics, 2006, 167, 39-42.	1.0	6
157	MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Human Molecular Genetics, 2006, 15, 933-942.	2.9	116
158	CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leukemia Research, 2005, 29, 981-982.	0.8	12
159	Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas. Experimental Dermatology, 2005, 14, 883-890.	2.9	17
160	Absence of CHEK2 mutations in Spanish families with hereditary breast cancer. Cancer Genetics and Cytogenetics, 2005, 161, 93-95.	1.0	14
161	Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma. Cancer Genetics and Cytogenetics, 2005, 163, 160-163.	1.0	11
162	Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry. Tumor Biology, 2005, 26, 25-30.	1.8	12

#	ARTICLE	IF	CITATIONS
163	Clonal proliferation of cyclin D1â€“positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?. Human Pathology, 2005, 36, 1232-1237.	2.0	41
164	Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: A FISH study. Urology, 2005, 65, 913-918.	1.0	14
165	Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry. Breast Cancer Research, 2005, 7, R267-73.	5.0	76
166	Gastrointestinal Involvement in Mantle Cell Lymphoma (MCL). A Prospective Clinical, Endoscopical, Pathological and Molecular Study.. Blood, 2005, 106, 4665-4665.	1.4	0
167	Lymphomatoid Papulosis Associated with Mycosis Fungoides: Clinicopathological and Molecular Studies of 12 Cases. Acta Dermato-Venereologica, 2004, 84, 463-468.	1.3	44
168	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene, 2004, 23, 8941-8949.	5.9	23
169	Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genetics and Cytogenetics, 2004, 148, 71-76.	1.0	18
170	Heterogeneity of structural abnormalities in the 7q31.3âˆ¼q34 region in myeloid malignancies. Cancer Genetics and Cytogenetics, 2004, 150, 136-143.	1.0	15
171	Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genetics and Cytogenetics, 2004, 151, 139-145.	1.0	14
172	Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 153, 16-25.	1.0	29
173	Intratumoral heterogeneity of HER2/neu and topoisomerase IIÎ± in breast cancer: a case with clonal monosomy 17. Cancer Genetics and Cytogenetics, 2004, 154, 89-90.	1.0	4
174	Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes and Cancer, 2004, 40, 140-145.	2.8	72
175	Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood, 2004, 103, 2427-2428.	1.4	18
176	Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL).. Blood, 2004, 104, 699-699.	1.4	0
177	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 141, 114-119.	1.0	16
178	Additional i(1)(q10) in a primitive neuroectodermal tumor type Merkel cell carcinoma as a primary cytogenetic change. Cancer Genetics and Cytogenetics, 2003, 142, 165-167.	1.0	5
179	Genomic rearrangements involving rDNA and centromeric heterochromatin in vulvar epidermoid carcinoma cell line A-431. Cancer Genetics and Cytogenetics, 2003, 143, 50-58.	1.0	2
180	Cytogenetic findings in familial B-cell chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 143, 172-173.	1.0	5

#	ARTICLE	IF	CITATIONS
181	RxFISH karyotype andMYCamplification in the HT-29 colon adenocarcinoma cell line. Genes Chromosomes and Cancer, 2003, 36, 319-320.	2.8	6
182	De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. Genes Chromosomes and Cancer, 2003, 36, 406-412.	2.8	27
183	HLA-G positive trophoblastic cells in transcervical samples and their isolation and analysis by laser microdissection and QF-PCR. Prenatal Diagnosis, 2003, 23, 34-39.	2.3	32
184	Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. Leukemia and Lymphoma, 2003, 44, 459-464.	1.3	24
185	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	1.4	121
186	Comparative Analysis of TCR-Î³ Gene Rearrangements by Genescan and Polyacrylamide Gel-electrophoresis in Cutaneous T-cell Lymphoma. Acta Dermato-Venereologica, 2003, 84, 6-11.	1.3	11
187	Analysis of T-Cell Receptor Î³ Gene Rearrangements by PCR-Genescan and PCR-Polyacrylamide Gel Electrophoresis in Early-Stage Mycosis fungoides/Large-Plaque Parapsoriasis. Dermatology, 2003, 207, 418-419.	2.1	8
188	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	1.4	158
189	Genetic characterization of the paraimmunoblastic variant of small lymphocytic lymphoma/chronic lymphocytic leukemia: A case report and review of the literature. Human Pathology, 2002, 33, 1145-1148.	2.0	5
190	Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance. Cancer Genetics and Cytogenetics, 2002, 132, 25-29.	1.0	10
191	Translocation (5;17)(q13;q21) in a case with precursor T-lymphoblastic lymphoma/leukemia. Cancer Genetics and Cytogenetics, 2002, 132, 81-82.	1.0	1
192	Pentasomy 21 with two isochromosomes 21 in a case of acute myeloid leukemia without maturation. Cancer Genetics and Cytogenetics, 2002, 132, 71-73.	1.0	7
193	A new case of acute nonlymphocytic leukemia (Frenchâ€“Americanâ€“British subtype M1) with double minutes and c-MYC amplification. Cancer Genetics and Cytogenetics, 2002, 132, 161-164.	1.0	6
194	Monosomy 15 in chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics, 2002, 134, 165-167.	1.0	2
195	Clinical Utility of a Multiprobe FISH Assay in Voided Urine Specimens for the Detection of Bladder Cancer and its Recurrences, Compared with Urinary Cytology. European Urology, 2002, 42, 547-552.	1.9	74
196	Report of 46,XX/46,XY/47,XXY/48,XXYY mosaicism in an adult phenotypic male. American Journal of Medical Genetics Part A, 2002, 111, 215-217.	2.4	8
197	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood, 2001, 98, 2837-2844.	1.4	125
198	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	3.7	126

#	ARTICLE	IF	CITATIONS
199	New t(11;12)(q12;q11) characterized by RxFISH in a patient with T-cell large granular lymphocyte leukemia. Cancer Genetics and Cytogenetics, 2001, 125, 70-73.	1.0	3
200	Isochromosome +i(3)(q10) in a new case of persistent polyclonal B-cell lymphocytosis (PPBL). European Journal of Haematology, 2000, 64, 344-346.	2.2	0
201	Cytogenetic and Fluorescence In Situ Hybridization Studies in Four Cases of Plasma Cell Leukemia. Cancer Genetics and Cytogenetics, 2000, 121, 163-166.	1.0	1
202	Dicentric (17;18) in a Case of Atypical B-Cell Chronic Lymphocytic Leukemia. Cancer Genetics and Cytogenetics, 2000, 121, 194-197.	1.0	6
203	A New Case of Turner Syndrome Associated with Multiple Myeloma. Cancer Genetics and Cytogenetics, 2000, 117, 80-81.	1.0	4
204	Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes. British Journal of Haematology, 2000, 110, 241-243.	2.5	8
205	Cytogenetic Findings in Five Patients with Hairy Cell Leukemia. Cancer Genetics and Cytogenetics, 1999, 110, 41-43.	1.0	16
206	Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma. Cancer Genetics and Cytogenetics, 1999, 111, 92-98.	1.0	31
207	Two New Cases of Near-Tetraploidy in Adult Acute Myeloid Leukemia. Cancer Genetics and Cytogenetics, 1998, 102, 131-134.	1.0	11
208	Cytogenetic Abnormalities in Three Patients with B-Cell Prolymphocytic Leukemia. Cancer Genetics and Cytogenetics, 1998, 103, 43-45.	1.0	12
209	Coexistence of tetrasomy 8 and trisomy 8 in a case with myeloid metaplasia with myelofibrosis. Cancer Genetics and Cytogenetics, 1997, 94, 147-150.	1.0	9
210	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone Bâ€cell lymphoma. British Journal of Haematology, 1997, 98, 446-449.	2.5	56
211	Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes and Cancer, 1997, 18, 84-93.	2.8	150
212	Trisomy 13 in a patient with a myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 1995, 81, 185.	1.0	5
213	Cytogenetic studies in five patients with SÃ©zary syndrome. Cancer Genetics and Cytogenetics, 1994, 75, 130-132.	1.0	11
214	A new case of t(14;19) (q32;q13) in a patient with follicular lymphoma in leukemic phase. Cancer Genetics and Cytogenetics, 1994, 75, 72-73.	1.0	11
215	A case of monosomy 20 in an adult acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 1993, 69, 165.	1.0	2
216	Trisomy 4 in a patient with acute myelomonocytic leukemia (M4). Cancer Genetics and Cytogenetics, 1993, 70, 152.	1.0	0

#	ARTICLE	IF	CITATIONS
217	A new chromosomal anomaly associated with mature B-cell chronic lymphoproliferative disorders: del(7)(q32). Cancer Genetics and Cytogenetics, 1993, 65, 170-172.	1.0	19
218	Cytogenetic studies in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 1992, 60, 117-124.	1.0	20
219	New chromosomal abnormality. Cancer Genetics and Cytogenetics, 1992, 60, 131-134.	1.0	1
220	G-banding improvement for the MAC method. Cancer Genetics and Cytogenetics, 1991, 51, 41-44.	1.0	7
221	Isochromosome 14q in myeloid dysplastic disorder. Cancer Genetics and Cytogenetics, 1991, 54, 133-134.	1.0	13
222	Acute lymphoblastic leukemia with t(4;11) in a patient previously exposed to a carcinogen. Cancer Genetics and Cytogenetics, 1990, 49, 133-136.	1.0	17
223	Translocation (2;7)(p13;q36) in a case of acute nonlymphocytic leukemia evolving from a myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 1988, 35, 199-204.	1.0	1